Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study
2013
Background
Oral and intravenous formulations of ciprofloxacin have established efficacy and safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis’ PulmoSphere™ technology has been developed to deliver high concentrations of ciprofloxacin to the lung with low systemic exposure using a portable and convenient passive dry powder inhaler (Novartis’ T-326 inhaler).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
38
References
52
Citations
NaN
KQI